We are live on ! Find out more
ONCT icon

Oncternal Therapeutics

Delisted

ONCT was delisted on the 2nd of December, 2024.

34 hedge funds and large institutions have $8.41M invested in Oncternal Therapeutics in 2016 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 3 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.06% less ownership

Funds ownership: 10.83% → 10.77% (-0.06%)

6% less funds holding

Funds holding: 36 → 34 (-2)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

45% less capital inflows, than outflows

Capital inflows: $50.5K | Capital outflows: $91.5K

50% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 6

Holders
34
Holders Change
-2
Holders Change %
-5.56%
% of All Funds
0.91%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
3
Reduced
6
Closed
5
Calls
$5​K
Puts
–
Net Calls
+$5​K
Net Calls Change
+$4​K

ONCT Hedge Fund Activity: Q2 2016 in Review

34 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics (ONCT) for Q2 2016, worth a combined $8.41M — up 9.4% from $7.68M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of ONCT and 3 opened new positions — a net loss of 2 holders — while 6 trimmed existing stakes and 3 added.

The largest buyer was Goldman Sachs, adding an estimated $22.4K. The largest seller was Group One Trading, exiting entirely with an estimated $28K sold.

  • 34 institutional investors held Oncternal Therapeutics (ONCT) as of Q2 2016, down from 36 in Q1 2016.
  • Funds reported $8.41M of Oncternal Therapeutics stock for Q2 2016, up 9.4% quarter-over-quarter.
  • 3 funds opened new Oncternal Therapeutics positions in Q2 2016 and 5 closed out, a net change of -2 holders.
  • The largest Oncternal Therapeutics buyer in Q2 2016 was Goldman Sachs, an estimated $22.4K added.
  • The largest Oncternal Therapeutics seller in Q2 2016 was Group One Trading, an estimated $28K sold.

Based on aggregated 13F filings for Q2 2016.